This module is intended for medical oncologists interested in the underlying research behind metastatic melanoma therapies and management of the most common associated treatment side-effects. Included within this 45 minute module are: summaries of landmark trials in the field of melanoma, associated published commentaries, and relevant case-based scenarios with response feedback.
Review the outcomes of seminal publications and clinical trials that have led the changes in management for metastatic melanoma
Anticipate the most common and serious side effects of targeted therapies
Identify the best management options for side effects of melanoma therapy
This program was supported by educational grants from GlaxoSmithKline and Bristol-Myers Squibb.
This activity is an Accredited Self-Assessment Program (Section 3) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada, and approved by Continuing Professional Development, Schulich School of Medicine & Dentistry, Western University.
Dr. Kathryn Roth (Scientific Committee Chair), MD, FRCPC Assistant Professor, Department of Otolaryngology, Western University, London, ON
Dr. Scott Ernst, MD, FRCPC Division Head, Medical Oncology, Department of Oncology, Western University, London, ON
Dr. Alex Hammond, MD, BSC, MBBCH, ABRT, FRCPC Professor, Department of Oncology, Western University, London, ON
Michael Brock, MSc Educational Developer, Schulich School of Medicine & Dentistry, Western University, London, ON
Michael Murray, MSc Medical Writer, Schulich School of Medicine & Dentistry, Western University, London, ON